• To date the modes of actions of pharmaceuticals

  2024-11-19

  

  To date, the modes of actions of pharmaceuticals in humans and mammals are well-known (Fent et al., 2006), whereas knowledge of aquatic organisms, particularly invertebrates, is limited. This is problematic as these contaminants/pollutants have potentially harmful effects on wildlife organisms that

• The present study has several limitations First the

  2024-11-19

  

  The present study has several limitations. First, the results were obtained using RAW264.7 cells, which are derived from BALB/c mice infected with the Abelson leukemia virus (Raschke et al., 1978). However, these cells, which are a commonly used mouse macrophage cell line, show properties similar to

• glucose transport proteins br Materials and methods br Resul

  2024-11-19

  

  Materials and methods Results To explore the potential role of autophagy in drug resistance, we firstly performed immunohistochemistry to compare the glucose transport proteins of p62 in paired primary, metastatic, and recurrent tumor tissues from 26 ovarian cancer patients. The expression of

• br Contemporary understanding for alcoholic cardiomyopathy

  2024-11-19

  

  Contemporary understanding for alcoholic cardiomyopathy Up-to-date, a number of theories are postulated for alcoholic cardiomyopathy including generation of mitochondrial reactive oxygen species (ROS), oxidative stress, neurohormonal overactivation (catecholamines and angiotensin II), apoptosis a

• In PMCA Mg favors the conversion E P E P

  2024-11-19

  

  In PMCA, Mg2+ favors the conversion E1P → E2P [13] and, as in SERCA [11], it accelerates the phosphorylation displacing the E1–E2 equilibrium towards E1. In SERCA, Sørensen et al. [41], proposed that ATP reacts by an associative mechanism mediated by two Mg2+ ions to form an aspartyl-phosphorylated

• br Conflicts of interest br Introduction Arginase catalyzes

  2024-11-19

  

  Conflicts of interest Introduction Arginase catalyzes the reaction in which l-arginine is converted to l-ornithine and urea. In humans, two arginase isoenzymes have been identified, arginase 1 and arginase 2, that differ in cellular location and tissue distribution [1]. Both arginase enzymes a

• N1-Methyl-ATP mg Chlorogenic acid an abundant polyphenol fou

  2024-11-19

  

  Chlorogenic N1-Methyl-ATP mg (7), an abundant polyphenol found in coffee and the human diet, has various biological activities including antioxidant and anticancer effects [54]. Jiang et al. reported that compound 7 had a selective cytotoxic activity on human oral tumor cells (HSG, HSC-2) as compar

• br Conclusion br Competing interests br Funding The Bolger P

  2024-11-19

  

  Conclusion Competing interests Funding The Bolger Prostate Cancer Research Fund (no grant number), the National Institute of General Medical Sciences of the National Institutes of Health (1-R01-GM58553, G. B. Bolger, principal investigator), and the National Cancer Institute of the NIH to t

• EPSP analogs were retrieved from

  2024-11-19

  

  EPSP analogs were retrieved from PubChem database and docking procedure yielded about eight best binding analogs (Fig. 10). The selected molecules were further assessed for their theoretical Ki values using AUTODOCK software version 4. The predicted binding efficiency of retrieved analogs was estima

• MSG model is well characterized

  2024-11-18

  

  MSG model is well characterized and widely used because it is not influenced by dietary components and because it mimics a lesion in the arcuate nucleus and lateral hypothalamus that can occur in chronic obese patients (Moraes et al., 2009, Purkayasta and Cai, 2013). High fat fed diet is amongst the

• In view of the ubiquitous distribution

  2024-11-18

  

  In view of the ubiquitous distribution of the arachidonate 12S-lipoxygenase isoforms and the variety of cellular reactions influenced by the resulting arachidonate metabolites, these products widely play important roles in many biological systems. The development of new type-specific inhibitors of t

• Recently a Phase III study demonstrated that alectinib

  2024-11-18

  

  Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat

• There are some limitations and further experiments

  2024-11-18

  

  There are some limitations and further experiments that are required. First, to our surprise, measurement of the cardiomyocyte cross-sectional area in Akt1−/−/iAkt2 KO mice showed comparable areas to WT mouse despite of reduced heart weight. In addition to measuring cardiomyocyte cross-sectional are

• Very recently Niessen et al have described the resensitizing

  2024-11-18

  

  Very recently, Niessen et al. have described the resensitizing effect of MB327 on nAChR performing solid-supported membrane (SSM)-based electrophysiological experiments (Niessen et al., 2016) using plasma membrane preparations obtained from Torpedo californica. These findings validated and underline

• For the NSCLC patients with EGFR

  2024-11-18

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

7945 records 88/530 page Previous Next First page 上5页 8687888990 下5页 Last page